Medical device company FPH has more than halved since its heady Covid days illustrating perfectly that stock prices aren’t a perfect science with huge swings in optimism/pessimism taking companies well away from their fair value. The stock was extremely popular during the Covid panic due to its respiratory care products but the business has failed to deliver the lift in profits many expected.
- We can see FPH bouncing back toward $20 but we need a catalyst to ignite our interest.
MM is neutral FPH
Add To Hit List
